

Avagenesis Corp. to Present at Cantech Investment Conference 2015 in Toronto

January 8, 2015 – Calgary, Alberta: Avagenesis Corp. (“Avagenesis” or the “Company”) (TSXV: VVA), is pleased to announce that the Company will be attending the Cantech Investment Conference, January 15, 2015, in Toronto, Ontario at the Metro Toronto Convention Centre 255 Front Street West.

There will be a corporate presentation at 1:00 pm by Avagenesis’ CFO, Alan Tam. Company representatives will also be available during the conference at Booth #108.

The Cantech Investment Conference brings together the top thought leaders, the fastest growing companies and the most influential investors in the country for a full day exposition. It is considered to be the ultimate showcase for Canadian technology development and investor opportunities.

About Avagenesis Corp.

Avagenesis is a biotechnology company engaged in the commercialization of medical technologies for use in the practice of regenerative medical aesthetics. Avagenesis’ development activities are focused on the complex task of efficiently isolating high quality, viable and potent adipose-derived adult stem cells and regenerative cells using patent-pending and patented bioprocessing and cell isolation technology.

Neither the Exchange nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Avagenesis' current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that Avagenesis may not successfully transition to a clinical stage company and the risk that Avagenesis may not successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Avagenesis. Avagenesis cautions the reader that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and Avagenesis is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.

Further Information

For further information, please contact:

Avagenesis Corp.

Alan Tam, PFP, CPA, CA
Chief Financial Officer
Telephone: (604) 377-7575